Enliven Therapeutics Financials
| ELVN Stock | 21.68 0.18 0.84% |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 17.11 | 9.25 |
|
|
Investors should never underestimate Enliven Therapeutics' ability to pay suppliers on time, ensure interest payments are not accumulating, and correctly time where and how to reinvest extra cash. Individual investors need to monitor Enliven Therapeutics' cash flow, debt, and profitability to make informed and accurate decisions about investing in Enliven Therapeutics.
Net Income |
|
Enliven | Select Account or Indicator |
Understanding current and past Enliven Therapeutics Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Enliven Therapeutics' financial statements are interrelated, with each one affecting the others. For example, an increase in Enliven Therapeutics' assets may result in an increase in income on the income statement.
Enliven Therapeutics Stock Summary
Enliven Therapeutics competes with Pmv Pharmaceuticals, Cullinan Oncology, Immuneering Corp, Aerovate Therapeutics, and MoonLake Immunotherapeuti. Enliven Therapeutics is entity of United States. It is traded as Stock on NASDAQ exchange.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Instrument | USA Stock View All |
| Exchange | NASDAQ Exchange |
| ISIN | US29337E1029 |
| CUSIP | 29337E102 45249V107 |
| Location | Massachusetts; U.S.A |
| Business Address | 6200 Lookout Road, |
| Sector | Pharmaceuticals |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | www.enliventherapeutics.com |
| Phone | 720 647 8519 |
Enliven Therapeutics Key Financial Ratios
| Return On Equity | -0.31 | ||||
| EBITDA | (81.93 M) | ||||
| Net Income | (71.58 M) | ||||
| Book Value Per Share | 6.10 X | ||||
| Market Capitalization | 1.06 B |
Enliven Therapeutics Key Balance Sheet Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Total Assets | 131.0M | 113.3M | 83.3M | 271.9M | 312.6M | 328.3M | |
| Other Current Liab | 565K | 3.1M | 6.0M | 25.0M | 28.8M | 30.2M | |
| Net Debt | (130.3M) | (109.9M) | (75.2M) | (99.8M) | (89.8M) | (94.3M) | |
| Retained Earnings | (20.5M) | (45.2M) | (82.9M) | (154.4M) | (139.0M) | (132.1M) | |
| Accounts Payable | 808K | 2.5M | 3.4M | 532K | 611.8K | 581.2K | |
| Cash | 130.4M | 110.0M | 75.5M | 100.1M | 115.2M | 68.8M | |
| Other Current Assets | 222K | 646K | 2.2M | 13.0M | 15.0M | 15.7M | |
| Total Liab | 151.3M | 156.2M | 160.1M | 26.0M | 29.9M | 28.4M | |
| Total Current Assets | 130.6M | 110.7M | 77.8M | 266.2M | 306.1M | 321.4M |
Enliven Therapeutics Key Income Statement Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Operating Income | (9.3M) | (24.8M) | (38.8M) | (83.5M) | (75.2M) | (71.4M) | |
| Research Development | 8.2M | 20.5M | 31.0M | 64.6M | 74.3M | 78.0M | |
| Ebitda | (9.3M) | (24.6M) | (38.6M) | (81.9M) | (73.7M) | (70.1M) | |
| Income Before Tax | (19.0M) | (24.7M) | (37.7M) | (71.6M) | (64.4M) | (61.2M) | |
| Income Tax Expense | (31K) | (22K) | 88K | 1.3M | 1.5M | 1.6M | |
| Ebit | (9.4M) | (24.8M) | (38.8M) | (82.2M) | (74.0M) | (70.3M) | |
| Net Income | (18.9M) | (24.7M) | (37.8M) | (71.6M) | (64.4M) | (61.2M) | |
| Gross Profit | (97K) | (99K) | (622K) | (297K) | (267.3K) | (280.7K) | |
| Cost Of Revenue | 97K | 99K | 622K | 297K | 341.6K | 252.6K |
Enliven Therapeutics Key Cash Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Change In Cash | 121.5M | (20.3M) | (34.5M) | 24.6M | 22.1M | 23.3M | |
| Free Cash Flow | (9.0M) | (19.3M) | (32.7M) | (61.4M) | (55.3M) | (52.5M) | |
| Other Non Cash Items | 9.7M | 3.8M | 1.7M | (4.3M) | (4.9M) | (4.7M) | |
| Capital Expenditures | 461K | 191K | 612K | 149K | 171.4K | 244.0K | |
| End Period Cash Flow | 130.4M | 110.1M | 75.6M | 100.2M | 115.2M | 68.9M | |
| Net Income | (19.0M) | (24.7M) | (37.7M) | (71.6M) | (64.4M) | (61.2M) | |
| Depreciation | 45K | 115K | 215K | 297K | 341.6K | 358.6K |
Enliven Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Enliven Therapeutics's current stock value. Our valuation model uses many indicators to compare Enliven Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Enliven Therapeutics competition to find correlations between indicators driving Enliven Therapeutics's intrinsic value. More Info.Enliven Therapeutics is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At this time, Enliven Therapeutics' Return On Equity is very stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Enliven Therapeutics' earnings, one of the primary drivers of an investment's value.Enliven Therapeutics Systematic Risk
Enliven Therapeutics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Enliven Therapeutics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twenty with a total number of output elements of fourty-one. The Beta measures systematic risk based on how returns on Enliven Therapeutics correlated with the market. If Beta is less than 0 Enliven Therapeutics generally moves in the opposite direction as compared to the market. If Enliven Therapeutics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Enliven Therapeutics is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Enliven Therapeutics is generally in the same direction as the market. If Beta > 1 Enliven Therapeutics moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Enliven Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Enliven Therapeutics' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Enliven Therapeutics growth as a starting point in their analysis.
Price Earnings To Growth Ratio |
|
Enliven Therapeutics February 16, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Enliven Therapeutics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Enliven Therapeutics. We use our internally-developed statistical techniques to arrive at the intrinsic value of Enliven Therapeutics based on widely used predictive technical indicators. In general, we focus on analyzing Enliven Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Enliven Therapeutics's daily price indicators and compare them against related drivers.
| Information Ratio | (0.11) | |||
| Maximum Drawdown | 19.31 | |||
| Value At Risk | (5.04) | |||
| Potential Upside | 5.14 |
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Enliven Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. To learn how to invest in Enliven Stock, please use our How to Invest in Enliven Therapeutics guide.You can also try the Bollinger Bands module to use Bollinger Bands indicator to analyze target price for a given investing horizon.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Enliven Therapeutics. If investors know Enliven will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Enliven Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Enliven Therapeutics is measured differently than its book value, which is the value of Enliven that is recorded on the company's balance sheet. Investors also form their own opinion of Enliven Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Enliven Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Enliven Therapeutics' market value can be influenced by many factors that don't directly affect Enliven Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Enliven Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Enliven Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Enliven Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.